What's in IVI Madrid's pipeline?

IVI Madrid has 8 drugs in our index: 5 marketed, 0 filed, 1 in Phase 3, 1 in Phase 2, 1 in Phase 1.

Which companies overlap with IVI Madrid's portfolio?

Top competitors by shared drug class: Organon and Co, Amgen, Brigham and Women's Hospital, Azienda USL Modena, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/ivi-madrid.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

IVI Madrid — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

IVI Madrid pipeline: 5 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 1 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Levonorgestrel and ethinylestradiol	Levonorgestrel and ethinylestradiol	marketed	Combined oral contraceptive	Progesterone receptor (levonorgestrel); estrogen receptor (ethinylestradiol)	Contraception / Reproductive Health
Urinary FSH	Urinary FSH	marketed	Gonadotropin	FSH receptor (FSHR)	Reproductive Medicine / Fertility
Biosimilar recombinant FSH	Biosimilar recombinant FSH	marketed	Gonadotropin; Biosimilar	FSH receptor (FSHR)	Reproductive Medicine / Fertility
triptorelin, recombinant LH	triptorelin, recombinant LH	marketed	GnRH agonist with recombinant LH supplementation	GnRH receptor; LH receptor	Reproductive Medicine / Fertility
human menopausal gonadotropin	human menopausal gonadotropin	marketed	Gonadotropin	FSH receptor (FSHR) and LH receptor (LHCGR)	Reproductive Medicine / Fertility
Administration of letrozole	Administration of letrozole	phase 3	Aromatase inhibitor	Aromatase (CYP19A1)	Oncology

Therapeutic area mix

Reproductive Medicine / Fertility · 4
Contraception / Reproductive Health · 1
Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Organon and Co · 2 shared drug classes
Amgen · 1 shared drug class
Brigham and Women's Hospital · 1 shared drug class
Azienda USL Modena · 1 shared drug class
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · 1 shared drug class
Bezmialem Vakif University · 1 shared drug class
AstraZeneca · 1 shared drug class
Ain Shams Maternity Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for IVI Madrid:

Cite this brief

Drug Landscape (2026). IVI Madrid — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ivi-madrid. Accessed 2026-06-10.